Skip to main content

Table 1 Demographic information for the 9 patients studied, EDSS scores and relapse summary information

From: Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate

No.

Age

Gender

Months followed

1st attack

Type of relapses

Relapses before starting MTX

Relapse on MTX

Treatment history

Months on MTX

Initial EDSS

Final EDSS

1

40

M

62

Myelitis

Myelitis

4

2

Stabilized on CTX* for 6 months, MTX** started as step down strategy, continued during last visit.

54

6.5

1.5

2

71

F

13

Optic Neuritis

Optic Neuritis and Myelitis

10

0

MTX started initially, continued during last visit.

11

5.5

3

3

62

F

146

Myelitis

Myelitis

5

1

MTX started initially, changed to MMF^^ briefly but due to S/E again started on MTX.

24

6.5

6.5

4

38

F

143

Myelitis

Optic Neuritis and Myelitis

7

0

Stabilized on CTX for 6 months, MTX started as step down strategy, continued during last visit.

60

4

4

5

46

F

114

Optic Neuritis

Optic Neuritis and Myelitis

8

2

Initially on AZA*** then following relapses MTX started, continued during last visit.

29

4

4

6

74

F

62

Myelitis

Myelitis

4

2

MTX started initially, continued during last visit.

52

4.5

5.5

7

54

F

85

Myelitis

Optic Neuritis and Myelitis

4

3

Stabilized on CTX for 6 months. MTX started as step down strategy, changed MTX to MMF due to increasing relapses and later to RTX^^^.

24

2

4.5

8

57

M

59

Myelitis

Myelitis

2

3

MTX started initially, MTX changed to MMF following continuing relapses and later to RTX.

7

3.5

5.5

9

52

F

62

Myelitis

Optic Neuritis and Myelitis

3

4

MTX started initially, RTX following continued relapses.

52

2.5

2.5

  1. *CTX-cyclophosphamide, **MTX-methotrexate, S/E-side effect, ***AZA-azathioprine, ^^MMF-mycophenolate mofetile, ^^^RTX-rituximab.